|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Leukemia, T-Cell | |||||
| Lymphoma, T-Cell, Cutaneous | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Leukemia | |||||
| Leukemia-Lymphoma, Adult T-Cell | |||||
| Lymphoma | |||||
| Lymphoma, T-Cell | |||||
| Mycosis Fungoides | |||||
| Sezary Syndrome | |||||
| 3 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Leukemia, Lymphoid | |||||
| Lymphatic Diseases | |||||
| Lymphoma, Non-Hodgkin | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Daclizumab | |||||
| 5 | More general drug interventions related to this trial | ||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 6 | Sponsors listed in this trial | ||||
| National Cancer Institute (NCI) | |||||